Faeth Therapeutics stock gets $60 target on Roche collaboration
Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.
How this was made
The 30-second read
Why it matters
The Roche collaboration and supply agreement provide a concrete next-step in testing PIKTOR with a next-generation endocrine backbone, supporting the thesis that the regimen can extend beyond paclitaxel-containing endometrial approaches.
Market read
Traders may reassess near-term risk/reward for FTH as the Roche partnership adds a tangible development pathway, even as the stock remains near lows after a steep recent decline.
What to watch
Key overhangs are regulatory execution and durability, and the article highlights the stock’s weak near-term momentum after a large selloff, which can cap upside until new trial data land.
Background
Faeth is developing PIKTOR (serabelisib plus sapanisertib) and is sponsoring Phase 1b/2 PIK-101; Roche supplies giredestrant (an oral SERD degrader) for a new HR+/HER2- combination trial.
Ticker impact
Faeth (FTH) announced a Roche clinical-trial collaboration and supply agreement to test PIKTOR with giredestrant in HR+/HER2- advanced breast cancer.
Likely upward bias as investors price improved probability of regulatory execution and durability, despite recent sharp selloff.
The article ties the Roche deal to a specific combination regimen and reiterates bullish analyst targets, while also noting the stock’s recent drawdown and near-52-week-low positioning.
Market effects
Reinforces investor appetite for targeted oncology combinations and endocrine backbone upgrades in HR+/HER2- breast cancer.
Limited, primarily affects US small/mid-cap biotech sentiment and the XBI complex.
Roche involvement may modestly lift cross-Atlantic biotech collaboration sentiment, but no broader market catalyst is indicated.
Counterpoint
The collaboration is an operational step, not a definitive efficacy or regulatory milestone, so the market may fade the initial optimism if trial endpoints or durability disappoint.
Key entities
- companyFaeth Therapeutics
NASDAQ-listed biotech developing PIKTOR; subject of the collaboration and analyst target reiterations.
- companyRoche
Supplies giredestrant and collaborates on the HR+/HER2- advanced breast cancer trial combination.
- clinical_trialPIK-101
Faeth-sponsored Phase 1b/2 trial evaluating PIKTOR in combination with giredestrant.
- clinical_trialPIK-201
Phase 2 trial in advanced endometrioid endometrial cancer with preliminary response and PFS figures cited in the article.

